Method for inhibition or treatment of colon tumorigenesis

Abstract

A method is provided for inhibiting the development of colon tumorigenesis in a mammal by administering to the mammal a pharmacologically effective amount of an isothiocyanate selected from the group consisting of sulforaphane and phenethyl isothiocyanate.

1 - 20 . (canceled)  
   
   
       21 . A method for inhibiting colon tumor development in a mammal, said method comprising administering to the mammal a pharmacologically effective amount of an isothiocyanate selected from the group consisting of sulforaphane, phenethyl isothiocyanate and N-acetylcysteine conjugates thereof.  
   
   
       22 . A method according to  claim 21 , wherein the isothiocyanate is sulforaphane.  
   
   
       23 . A method according to  claim 21 , wherein the isothiocyanate is phenethyl isothiocyanate.  
   
   
       24 . A method according to  claim 21 , wherein the isothiocyanate is the N-acetylcysteine conjugate of sulforaphane.  
   
   
       25 . A method according to  claim 21 , wherein the isothiocyanate is the N-acetylcysteine conjugate of phenethyl isothiocyanate.  
   
   
       26 . A method according to  claim 21 , wherein the isothiocyanate is administered to the mammal as a dietary supplement.  
   
   
       27 . A method according to  claim 21 , wherein the mammal is a human.  
   
   
       28 . A method according to  claim 27 , wherein the isothiocyanate is administered to the human in a dosage of between about 0.5 and 12 mg/kg body weight per day.  
   
   
       29 . A method according to  claim 21 , wherein the isothiocyanate is administered to the mammal in a substantially purified form.  
   
   
       30 . A method according to  claim 21 , wherein the isothiocyanate is administered to the mammal in a composition comprising the isothiocyanate and a pharmacologically acceptable carrier, excipient or diluent.  
   
   
       31 . A method according to  claim 22 , wherein the sulforaphane is administered to the mammal in a substantially purified form.  
   
   
       32 . A method according to  claim 22 , wherein the sulforaphane is administered to the mammal in a composition consisting essentially of the sulforaphane and a pharmacologically acceptable carrier, excipient or diluent.  
   
   
       33 . A method according to  claim 22 , wherein the mammal is a human and the sulforaphane is administered to the human in a dosage of between about 0.55 and 1.1 mg/kg body weight per day.  
   
   
       34 . A method according to  claim 23 , wherein the phenethyl isothiocyanate is administered to the mammal in a substantially purified form.  
   
   
       35 . A method according to  claim 23 , wherein the phenethyl isothiocyanate is administered to the mammal in a composition consisting essentially of the phenethyl isothiocyanate and a pharmacologically acceptable carrier, excipient or diluent.  
   
   
       36 . A method according to  claim 23 , wherein the mammal is a human and the phenethyl isothiocyanate is administered to the human in a dosage of between about 0.6 and 1.2 mg/kg body weight per day.  
   
   
       37 . A method according to  claim 24 , wherein the N-acetylcysteine conjugate of sulforaphane is administered to the mammal in a substantially purified form.  
   
   
       38 . A method according to  claim 24 , wherein the N-acetylcysteine conjugate of sulforaphane is administered to the mammal in a composition consisting essentially of the N-acetylcysteine conjugate of sulforaphane and a pharmacologically acceptable carrier, excipient or diluent.  
   
   
       39 . A method according to  claim 24 , wherein the mammal is a human and the N-acetylcysteine conjugate of sulforaphane is administered to the human in a dosage of between about 5.5 and 11 mg/kg body weight per day.  
   
   
       40 . A method according to  claim 25 , wherein the N-acetylcysteine conjugate of phenethyl isothiocyanate is administered to the mammal in a substantially purified form.  
   
   
       41 . A method according to  claim 25 , wherein the N-acetylcysteine conjugate of phenethyl isothiocyanate is administered to the mammal in a composition consisting essentially of the N-acetylcysteine conjugate of phenethyl isothiocyanate and a pharmacologically acceptable carrier, excipient or diluent.  
   
   
       42 . A method according to  claim 25 , wherein the mammal is a human and the N-acetylcysteine conjugate of phenethyl isothiocyanate is administered to the human in a dosage of between about 6.0 and 12 mg/kg body weight per day.